[1] Martinello M, Solomon S S, Terrault N A, et al. Hepatitis C[J]. Lancet, 2023, 402: 1085-1096.
[2] Taha G, Ezra L, Abu-Freha N. Hepatitis C Elimination: Opportunities and Challenges in 2023[J]. Viruses, 2023, 15: 1413.
[3] Di Marco L, La Mantia C, Di Marco V. Hepatitis C: Standard of Treatment and What to Do for Global Elimination[J]. Viruses, 2022, 14(3): 505.
[4] Cui F, Blach S, Manzengo Mingiedi C, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C[J]. Lancet Gastroenterol Hepatol, 2023, 8: 332-342.
[5] Calvaruso V, Petta S, Craxì A. Is global elimination of HCV realistic?[J]. Liver Int, 2018, 38 Suppl 1: 40-46.
[6] Kondili L A, Craxi A. Hepatitis C elimination: Tailoring the approach to each country’s needs and realities[J]. Hepatology, 2024, 80: 263-265.
[7] Kondili L A, Craxì A, Aghemo A. Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements[J]. Liver Int, 2021, 41: 649-655.
[8] Tian F, Forouzannia F, Feng Z, et al. Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries[J]. Hepatology, 2024,80:440-450.
[9] Wang Y, Cheng G, Lau G. Achieving WHO target of HCV control in Hong Kong: challenges and strategies[J]. Global Health & Medicine, 2021, 3: 276-282.
[10] Huang CF, Chen GJ, Hung CC, et al. HCV Microelimination for High-risk Special Populations[J]. J Infect Dis, 2023, 228:S168-S179.
[11] Midgard H, Weir A, Palmateer N, et al. HCV epidemiology in high-risk groups and the risk of reinfection[J]. J Hepatol, 2016, 65: S33-S45.
[12] Warkad S D, Nimse S B, Song K S, et al. HCV Detection, Discrimination, and Genotyping Technologies[J]. Sensors, 2018, 18: 3423.
[13] Chevaliez S. Strategies for the improvement of HCV testing and diagnosis[J]. Expert Rev Anti Infect Ther, 2019, 17: 341-347.
[14] Fiore V, Manca V, Colpani A, et al. Facing HCV as a Major Public Healthcare Threat in Italy: Epidemiology and Micro-Elimination Pathways among Underserved Populations[J]. Healthcare, 2023, 11: 2109.
[15] Isakov V, Nikityuk D. Elimination of HCV in Russia: Barriers and Perspective[J]. Viruses, 2022, 14: 790.
[16] Nevola R, Rosato V, Conturso V, et al. Can Telemedicine Optimize the HCV Care Cascade in People Who Use Drugs? Features of an Innovative Decentralization Model and Comparison with Other Micro-Elimination Strategies[J]. Biology,2022,11:805.
[17] Vo-Quang E, Pawlotsky J M. 'Unusual' HCV genotype subtypes: origin, distribution, sensitivity to direct-acting antiviral drugs and behaviour on antiviral treatment and retreatment[J]. Gut, 2024, 73: 1570-1582.
[18] European Association For The Study Of The Liver . Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series'[J]. J Hepatol, 2023, 78: 452.
[19] Rockstroh J K, Swan T, Chang J, et al. The path to hepatitis C elimination: who are we leaving behind and why[J] ? J Int AIDS Soc, 2023, 26: e26136.
[20] Kondili LA, Craxì A, Aghemo A. Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements[J]. Liver Int, 2021,41(4):649-655. |
